A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma

These findings suggest the opportunity for patient stratification and the potential for more durable antitumor immune responses in future clinical trials of this multimodal standard of care and combined immunotherapy regimen. ClinicalTrials.gov identifier: NCT03576612.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-03-17
DOI
https://doi.org/10.1093/neuonc/noaf079
Citations
4
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
6.50
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma

Xiaobu Ye, Louisa Little, Joy Fisher, Stephen Bagley et al.
4 citations
Neuro-Oncology
Glioma Diagnosis and Treatment
6.50
article

A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma

Xiaobu Ye, Louisa Little, Joy Fisher, Stephen Bagley, Mina Pichavant, Sean Lawler, Glenn Jay Lesser, Stuart A. Grossman, Garrett Nichols, Arati Desai, Pierpaolo Peruzzi, Frank S. Lieberman, Andrew J. Gentles, Diane M. Del Valle, Chandana Kakani, Patrick Y. Wen, Dzifa Y. Duose, Elad Sharon, Roy E. Strowd, Dan Triggs, Christine Camacho, Tobias Walbert, Ignacio I. Wistuba, Gheath Alatrash, Edgar Gonzalez‐Kozlova, Peixin Jiang, Alex Kong, Megan Mantica, E. Antonio Chiocca, Deanna L. Lane, Michal O. Nowicki, Steven Brem, Sean C. Bendall, Cara Haymaker, Laura K. Aguilar, Adrian W. Laxton, Seunghee Kim‐Schulze, Lenika Lopez, Jan Drappatz, Jessica Dwyer, Stephen B. Tatter, P. Andrew Futreal, Holden T. Maecker, Sacha Gnjatic, Francesca Barone, Caroline Duault, Mohammed Rafiqul Islam, Alexandre Reuben, Julia Mendoza‐Pérez, Ian Lee, Andrea G. Manzanera, James P. Snyder, Paul P. Tak, Estuardo Aguilar-Córdova
article en
4 citations

Abstract

These findings suggest the opportunity for patient stratification and the potential for more durable antitumor immune responses in future clinical trials of this multimodal standard of care and combined immunotherapy regimen. ClinicalTrials.gov identifier: NCT03576612.

Neuro-OncologyVol. 27(10)
Brigham and Women's Hospital (US), Mount Sinai Hospital (US), The University of Texas MD Anderson Cancer Center (US), Johns Hopkins University (US), Henry Ford Health System (US), Brown University (US), Johns Hopkins Medicine (US), Johns Hopkins Bayview Medical Center (US), University Medical Center (US), Henry Ford Hospital (US), Mount Sinai Medical Center (US), Mount Sinai Hospital (US), Center for Neuro-Oncology (US), Dana-Farber Cancer Institute (US), Translational Therapeutics (United States) (US), UPMC Hillman Cancer Center (US), University of Pittsburgh Medical Center (US), Celldex Therapeutics (United States) (US), Pediatric Brain Tumor Foundation (US), Wake Forest University (US), Mass General Brigham (US), University of Pennsylvania (US), Stanford University (US), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 4%
Glioma Diagnosis and Treatment
6.50
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.